Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the impact of infant respiratory syncytial virus on (1) paediatric intensive care bed capacity, (2) NHS elective care capacity, (3) GP visits, and (4) economic productivity.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England has not made specific assessments of the impact of infant respiratory syncytial virus (RSV) on paediatric intensive care bed capacity, National Health Service elective care capacity, and general practice visits, as RSV is often accompanied by other respiratory viruses and bacterial infections, and it is therefore difficult to measure the exact contribution of RSV. Neither has the Department assessed the wider productivity and economic benefits of RSV specifically.
The NHS plans for a wide range of scenarios ahead of each winter, and will continue to adapt plans based on respiratory infections surveillance, including RSV, and NHS activity data. This includes specialised commissioning led winter surge planning for paediatric critical care, as well as wider winter planning. For RSV specifically, this includes the annual immunisation programme, which continues to be managed and reviewed in accordance with advice from the Joint Committee on Vaccination and Immunisation (JCVI). For 2024 to 2025, preparedness may include rolling out a new RSV vaccination programme following the JCVI’s recommendations issued in September 2023, subject to approval from the Department.
The health impact of infant RSV was assessed in a scientific paper published in Lancet Regional Health Europe in January 2024, and has been assessed previously in scientific papers published by Public Health England and others. This work contributed to the JCVI’s assessment of RSV’s impact, and advice to implement an immunisation programme to prevent infant RSV.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment has she made of the potential merits of a men's health strategy for the economy.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Whilst no specific assessment has been made, we are already taking action to address the health issues that disproportionately impact men. This includes through policies announced on International Men’s Day, such as the appointment of a Men’s Health Ambassador, to raise the profile of men’s health issues. The Major Conditions Strategy will also focus on improving health outcomes linked to major condition areas like cancer, cardiovascular, and chronic respiratory diseases that disproportionately impact men.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what data they are gathering on countries currently implementing immunisation programmes for infant respiratory syncytial virus regarding (1) acceptance and uptake, and (2) hospitalisations.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The UK Health Security Agency continues to monitor international reporting. In the United States, as of 31 January 2024, maternal immunisation was 17.9%. By February 2024, 43% of infants under eight months old had received a dose of nirsevimab.
In Galicia, Spain, 92.9% of 5,357 infants born between 25 September 2023 and 4 February 2024 had nirsevimab, plus 79.7% of 5,823 in a catch-up programme. The peak of hospitalisation rate in infants under six months old was 102 per 100,000, for season 2023 to 2024 during the week starting 27 November 2023 compared to a median of 776 for seasons 2017 to 2018, 2018 to 2019 and 2019 to 2020, peaking during the first week of January 2024.
In Luxembourg, 84% of 1,524 infants born in hospital between early October and mid-December 2023 received nirsevimab. Luxembourg observed a decrease in hospitalisation in infants under six months old of 69% between the 2022 to 2023 and 2023 to 2024 respiratory syncytial virus seasons.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, what recent estimate his Department has made of the number of people affected by (a) respiratory and (b) fatigue conditions who may have their Universal Credit awards changed under the recently announced Work Capability Assessment reforms.
Answered by Mims Davies - Minister of State (Department for Work and Pensions)
In November last year we announced changes to the Work Capability Assessment (WCA) criteria, to deliver the right outcomes and reflect changes in work since the criteria were last comprehensively reviewed in 2011.
Changes to the WCA activities and descriptors will be implemented nationally no earlier than 2025. The majority of existing Universal Credit or Employment and Support Allowance claimants will not be affected by the WCA changes if they have already been assessed as having limited capability for work and work-related activity.
With these changes to the WCA criteria, 424,000* fewer people will be assessed as having limited capability for work and work-related activity by 2028-29 and will receive personalised support to help them move closer to employment. A further 33,000* individuals will be found fit for work by 2028-2029 and will receive more intensive support to search for and secure work than would be the case under the current WCA rules.
Estimates are not based on specific conditions because the WCA considers the impact that a person’s disability or health condition has on their ability to work, not the condition itself.
We will publish an Impact Assessment in due course.
Asked by: Dawn Butler (Labour - Brent Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to help ensure the Major Conditions Strategy improves breast cancer outcomes for ethnic minority women.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Reducing inequalities and improving breast cancer outcomes for ethnic minority women, including black women, is a priority for the Government. To support this work, NHS England has commissioned six new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients, including metastatic breast cancer. The Royal College of Surgeons began work on this audit in October 2022, and the first outcomes are expected in September 2024.
NHS England is also leading a programme of work to tackle healthcare inequalities centred around five clear priorities, which are set out in operational planning guidance for the health system. The Core20PLUS5 approach for adults has been rolled out as an NHS England framework to focus action on reducing inequalities on issues within the National Health Services’ direct influence, which are major contributors to inequalities in life expectancy through major conditions like cancer, cardiovascular disease, respiratory disease, and others, or Long-Term Plan priorities where stark inequalities are evident, such as maternity or severe mental illness.
The key actions for systems as highlighted in NHS England’s planning guidance for 2024/25 is to continue to deliver against the five strategic priorities for tackling health inequalities. Additionally, by the end of June 2024, NHS England aims to publish joined-up action plans to address health inequalities, and implement the Core20PLUS5 approach.
Improving earlier diagnosis of cancers, including breast cancer, is also a priority for the Government. The NHS has an ambition to diagnose 75% of cancers at stage 1 or 2 by 2028, which will help tens of thousands of people live for longer. Additionally, the new cancer standards developed and supported by cancer doctors and implemented in October 2023, will ensure patients are diagnosed faster, and that treatment starts earlier. In the 2023/24 Operational Planning Guidance, NHS England announced that it is providing over £390 million in cancer service development funding to Cancer Alliances in each of the next two years, to support the delivery of the strategy and the operational priorities for cancer, which includes increasing and prioritising diagnostic and treatment capacity.
Whilst the Major Conditions Strategy does not seek to describe everything that is being done, or could be done, to meet the challenges of individual conditions in silo, it instead focuses on the changes likely to make the most difference across the six groups of major conditions, including cancer.
Asked by: Dawn Butler (Labour - Brent Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve breast cancer outcomes amongst Black women.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Reducing inequalities and improving breast cancer outcomes for ethnic minority women, including black women, is a priority for the Government. To support this work, NHS England has commissioned six new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients, including metastatic breast cancer. The Royal College of Surgeons began work on this audit in October 2022, and the first outcomes are expected in September 2024.
NHS England is also leading a programme of work to tackle healthcare inequalities centred around five clear priorities, which are set out in operational planning guidance for the health system. The Core20PLUS5 approach for adults has been rolled out as an NHS England framework to focus action on reducing inequalities on issues within the National Health Services’ direct influence, which are major contributors to inequalities in life expectancy through major conditions like cancer, cardiovascular disease, respiratory disease, and others, or Long-Term Plan priorities where stark inequalities are evident, such as maternity or severe mental illness.
The key actions for systems as highlighted in NHS England’s planning guidance for 2024/25 is to continue to deliver against the five strategic priorities for tackling health inequalities. Additionally, by the end of June 2024, NHS England aims to publish joined-up action plans to address health inequalities, and implement the Core20PLUS5 approach.
Improving earlier diagnosis of cancers, including breast cancer, is also a priority for the Government. The NHS has an ambition to diagnose 75% of cancers at stage 1 or 2 by 2028, which will help tens of thousands of people live for longer. Additionally, the new cancer standards developed and supported by cancer doctors and implemented in October 2023, will ensure patients are diagnosed faster, and that treatment starts earlier. In the 2023/24 Operational Planning Guidance, NHS England announced that it is providing over £390 million in cancer service development funding to Cancer Alliances in each of the next two years, to support the delivery of the strategy and the operational priorities for cancer, which includes increasing and prioritising diagnostic and treatment capacity.
Whilst the Major Conditions Strategy does not seek to describe everything that is being done, or could be done, to meet the challenges of individual conditions in silo, it instead focuses on the changes likely to make the most difference across the six groups of major conditions, including cancer.
Asked by: Desmond Swayne (Conservative - New Forest West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment her Department made of the potential risks of discontinuing routine covid-19 testing of hospital patients prior to their discharge to care homes before.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The public health advice is that now is an appropriate point to end routine asymptomatic discharge testing for COVID-19, and move to a risk-based approach. A reduction in the severity of illness associated with the omicron variant, coupled with a high uptake of the vaccine among residents during the autumn COVID-19 vaccination booster, continued provision of infection prevention and control guidance, and the upcoming increased eligibility for COVID-19 treatments, demonstrates a reduced level of risk from COVID-19 in adult social care settings. In addition, epidemiological studies, and consensus reports from the early phases of the pandemic, suggest that hospital discharge was not dominant in the ingress of COVID-19 into care home settings.
The UK Health Security Agency’s (UKHSA) guidance on safe discharge and management of individuals with symptoms of an acute respiratory infection remains in place, and this will be kept under regular review. National Health Service trusts will have local discretion to re-introduce discharge or other forms of testing where clinically appropriate, following a risk assessment involving local authority public health teams, UKHSA Health Protection Teams, and care providers, as necessary in the decision making.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the HM Treasury:
To ask the Chancellor of the Exchequer, what discussions his Department has had with the Secretary of State for Health and Social Care on a respiratory syncytial virus vaccination programme.
Answered by Laura Trott - Chief Secretary to the Treasury
Ministers and officials across government meet regularly to discuss a wide range of issues, including routine and new vaccination programmes. If any RSV programmes are agreed to, they will be announced to the public and health professionals in due course.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how they plan to assess the impact of new immunisation programmes for infant respiratory syncytial virus on (1) hospitalisations, and (2) health inequality.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The UK Health Security Agency (UKHSA) monitors national immunisation programmes in England. The UKHSA’s Severe Acute Respiratory Infection Watch surveillance system collects weekly information on admissions to hospital with Respiratory Syncytial Virus (RSV), to monitor admission rates in each RSV season. If a programme is introduced, monitoring of its effectiveness would include thorough analysis of immunisation records, both infant or maternal, and laboratory results for patients needing healthcare for RSV-like illness. The UKHSA can also monitor RSV admissions by deprivation and ethnicity, using routine National Health Service records, when these become available following the RSV season. The UKHSA will also monitor inequalities in uptake of the RSV immunisation programmes, through its routine uptake data collections.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how they plan to assess the wider productivity and economic benefits of any new immunisation programmes for infant respiratory syncytial virus.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The independent Joint Committee for Vaccination and Immunisation (JCVI) advises the Department on the approach to vaccination and immunisation. The JCVI’s evaluation of the cost-effectiveness of a respiratory syncytial virus (RSV) programme was based on the health benefits of an infant RSV programme, and the potential healthcare cost savings from preventing cases and hospitalisations.
The Department did not ask the JCVI to complete an assessment of the wider productivity and economic benefits when determining the cost-effectiveness of a vaccination programme, and the Department did not assess this separately for RSV.